A compilation of national plans, policies and government actions for rare diseases in 23 countries

Intractable and Rare Diseases Research

Volumn 7, Issue 4, 2018, Pages 213-222

  Khosla, Neil ^a   Valdez, Rodolfo ^a  

^a NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

Program; Rare disease legislation; Strategy

Indexed keywords

ARGENTINA; AUSTRALIA; BRAZIL; BULGARIA; CANADA; CHILE; CHINA; COLOMBIA; FRANCE; GERMANY; GREECE; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH PROGRAM; INFORMATION RETRIEVAL; ITALY; JAPAN; LAW; MEXICO; PERU; PHILIPPINES; PORTUGAL; PUBLICATION; RARE DISEASE; REVIEW; SINGAPORE; SOUTH KOREA; SPAIN; TAIWAN; UNITED KINGDOM; UNITED STATES;

EID: 85058661451     PISSN: 21863644     EISSN: 2186361X     Source Type: Journal    
DOI: 10.5582/irdr.2018.01085     Document Type: Review

References (72)

1. Gammie T, Lu CY, Babar ZU. Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries. PLoS One. 2015; 10:e0140002.
2. Franco P. Orphan drugs: the regulatory environment. Drug Discov Today. 2013; 18:163-172.
3. van Weely S, Leufkens HGM. World Health Organization. Update on 2004 Background Paper, BP 6.19 Rare Diseases. http://www.who.int/medicines/areas/priority_medicines/BP6_19Rare.pdf (accessed July 27, 2018).
4. Eurordis. About Rare Diseases. https://www.eurordis.org/ about-rare-diseases (accessed July 27, 2018).
5. Forman J, Taruscio D, Llera VA, Barrera LA, Coté TR, Edfjäll C, Gavhed D, Haffner ME, Nishimura Y, Posada M, Tambuyzer E, Groft SC, Henter JI; International Conference for Rare Diseases and Orphan Drugs (ICORD). The need for worldwide policy and action plans for rare diseases. Acta Paediatr. 2012; 101:805-807.
6. Shire. Rare Disease Impact Report: Insights from patients and the medical community. https://globalgenes.org/wp-content/uploads/2013/04/ShireReport-1.pdf (accessed July 27, 2018).
7. Ouyang L, Grosse SD, Armour BS, Waitzman NJ. Health care expenditures of children and adults with spina bifida in a privately insured U.S. population. Birth Defects Res A Clin Mol Teratol. 2007; 79:552-558.
8. Hadjivasiliou A. EvaluatePharma. Orphan Drug Report 2014. http://info.evaluategroup.com/rs/evaluatepharmaltd/images/2014OD.pdf (accessed July 27, 2018).
9. Boström K, Nätterlund BS, Ahlström G. Sickness impact in people with muscular dystrophy: a longitudinal study over 10 years. Clin Rehabil. 2005; 19:686-694.
10. Cheung RY, Cohen JC, Illingworth P. Orphan drug policies: implications for the United States, Canada, and developing countries. Health Law J. 2004; 12:183-200.
11. GovTrack. H.R. 717 (107th): MD-CARE Act. https://www.govtrack.us/congress/bills/107/hr717/text (accessed July 27, 2018).
12. Mendell JR, Csimma C, McDonald CM, Escolar DM, Janis S, Porter JD, Hesterlee SE, Howell RR. Challenges in drug development for muscle disease: A stakeholders' meeting. Muscle Nerve. 2007; 35:8-16.
13. National Archives and Records Administration. Final Rule. 21 CFR Parts 136, 137, and 139. Fed Regist. 1996; 61:8781-8789.
14. Williams J, Mai CT, Mulinare J, Isenburg J, Flood TJ, Ethen M, Frohnert B, Kirby RS; Centers for Disease Control and Prevention. Updated Estimates of Neural Tube Defects Prevented by Mandatory Folic Acid Fortification ‒ United States, 1995-2011. MMWR Morb Mortal Wkly Rep. 2015; 64:1-5.
15. Food Fortification Initiative. Global Progress of Industrially Milled Cereal Grains. http://ffinetwork.org/global_progress/index.php (accessed July 27, 2018).
16. Taruscio D, Vittozzi L, Stefanov R. National Plans and Strategies on Rare Diseases in Europe. In: Advances in Experimental Medicine and Biology (Posada de la Paz M, Groft S, eds.). Springer Netherlands, Dordrecht, Netherlands, 2010; pp. 475-491.
17. Rodwell C, Aymé S. Rare disease policies to improve care for patients in Europe. Biochim Biophys Acta. 2015; 1852:2329-2335.
18. Commission of the European Communities . Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions on Rare diseases: Europe's challenges. http://ec.europa.eu/health/ph_threats/non_com/docs/rare_com_en.pdf (accessed July 27, 2018).
19. Moliner AM, Waligóra J. The European union policy in the field of rare diseases. Public Health Genomics. 2013; 16:268-277.
20. Moliner AM, Waligóra J. The European Union Policy in the Field of Rare Diseases. In: Rare Diseases Epidemiology: Update and Overview (Posada de la Paz M, Taruscio D, Groft SC, eds.). Springer International Publishing, Cham, Switzerland, 2017; pp. 561-587.
21. European Union. Reaching out to rare disease patients across Europe. http://ec.europa.eu/health/rare_diseases/docs/rd_booklet_2011_en.pdf (accessed July 27, 2018).
22. Lee DK, Wong B. An Orphan Drug Framework (ODF) for Canada. J Popul Ther Clin Pharmacol. 2014; 21:e42-46.
23. Rare Alliance Canada. Now is the Time: A Strategy for Rare Diseases is a Strategy for all Canadians. http:// www.rarealliancecanada.org/pdf/CORD_Canada_RD_ Strategy_22May15.pdf (accessed July 27, 2018).
24. McMillan HJ, Campbell C. We need a "made in Canada" orphan drug framework. CMAJ. 2017; 189:E1274-E1275.
25. Dharssi S, Wong-Rieger D, Harold M, Terry S. Review of 11 national policies for rare diseases in the context of key patient needs. Orphanet J Rare Dis. 2017; 12:63.
26. Balasubramanian G, Morampudi S, Chhabra P, Gowda A, Zomorodi B. An overview of Compassionate Use Programs in the European Union member states. Intractable Rare Dis Res. 2016; 5:244-254.
27. Hyry HI, Manuel J, Cox TM, Roos JC. Compassionate use of orphan drugs. Orphanet J Rare Dis. 2015; 10:100.
28. Denis A, Mergaert L, Fostier C, Cleemput I, Simoens S. A comparative study of European rare disease and orphan drug markets. Health Policy. 2010; 97:173-179.
29. Rare Voices Australia. Orphan Drugs Fact Sheet. http://rva.blob.core.windows.net/assets/uploads/files/Orphan_ Drugs_Fact_Sheet.pdf (accessed July 27, 2018).
30. Cui Y, Zhou X, Han J. China launched a pilot project to improve its rare disease healthcare levels. Orphanet J Rare Dis. 2014; 9:14.
31. Song P, He J, Li F, Jin C. Innovative measures to combat rare diseases in China: The national rare diseases registry system, larger-scale clinical cohort studies, and studies in combination with precision medicine research. Intractable Rare Dis Res. 2017; 6:1-5.
32. Wong Rieger D, Claxton W, Vines R, Padilla C, Tsang K, Hickinbotham L. An Asia pacific alliance for rare diseases. Patient. 2015; 8:11-17.
33. Republic of the Philippines House of Representatives. Sixteenth Congress Third Regular Session Republic Act No. 10747. An Act Promulgating a Comprehensive Policy in Addressing the Needs of Persons with Rare Disease. http://www.congress.gov.ph/legisdocs/ra_16/RA10747.pdf (accessed July 27, 2018).
34. Singapore Statutes Online. Medicines Act (Chapter 176, Section 9) Medicines (Orphan Drugs), (Exemption) Order, G.N. No. S 470/1991, Revised Edition 2005. https://sso.agc.gov.sg/SL/MA1975-OR12?DocDate=20050331&Vali dDate=20160122&TransactionDate=20160122 (accessed July 30, 2018).
35. Song P, Gao J, Inagaki Y, Kokudo N, Tang W. Rare diseases, orphan drugs, and their regulation in Asia: Current status and future perspectives. Intractable Rare Dis Res. 2012; 1:3-9.
36. Park O, Cho SY, Shin SY, Park J-S, Kim J, Han B-G. A strategic plan for the second phase (2013-2015) of the Korea biobank project. Osong Public Health Res Perspect. 2013; 4:107-116.
37. Orphanet. How specific legislation for rare diseases and orphan drugs is changing life for some patients in Taiwan. http://www.orpha.net/actor/EuropaNews/2009/doc/Taiwan. pdf (accessed July 30, 2018).
38. CheckOrphan. Argentina and Peru making progress with new rare disease laws legislated in both countries. http://www.checkorphan.org/news/argentina-and-peru-making-progress-with-new-rare-disease-laws-legislated-in-both-countries (accessed July 30, 2018).
39. Arnold RJ, Bighash L, Bryón Nieto A, Tannus Branco de Araújo G, Gay-Molina JG, Augustovski F. The role of globalization in drug development and access to orphan drugs: orphan drug legislation in the US/EU and in Latin America. F1000Res. 2015; 4:57.
40. Passos-Bueno MR, Bertola D, Horovitz DD, de Faria Ferraz VE, Brito LA. Genetics and genomics in Brazil: A promising future. Mol Genet Genomic Med. 2014; 2:280-291.
41. De Castro M, Restrepo CM. Genetics and Genomic Medicine in Colombia. Mol Genet Genomic Med. 2015; 3:84-91.
42. Pejcic AV, Iskrov G, Raycheva R, Stefanov R, Jakovljevic MM. Transposition and implementation of EU rare disease policy in Eastern Europe. Expert Rev Pharmacoecon Outcomes Res. 2017; 17:557-566.
43. Dunkle M, Pines W, Saltonstall PL. Advocacy Groups and Their Role in Rare Diseases Research. In: Rare Diseases Epidemiology (Posada de la Paz M, Groft SC, eds.). Springer Netherlands, Dordrecht, 2010; pp. 515-525.
44. Chaves Restrepo A, Denis M. International Society for Pharmacoeconomics and Outcomes Research. Rare Diseases in Latin America: Challenges and opportunities for the equitable attention and proposal of Patients Organizations. http://press.ispor.org/LatinAmerica/2017/09/rare-diseases-in-latin-america-challenges-and-opportunities-for-the-equitable-attention-and-proposal-of-patients-organizations/ (accessed July 30, 2018).
45. Richter T, Nestler-Parr S, Babela R, Khan ZM, Tesoro T, Molsen E, Hughes DA, International Society for Pharmacoeconomics and Outcomes Research Rare Disease Special Interest Group. Rare Disease Terminology and Definitions-A Systematic Global Review: Report of the ISPOR Rare Disease Special Interest Group. Value Health. 2015; 18:906-914.
46. Lochmüller H, Torrent I Farnell J, Le Cam Y, Jonker AH, Lau LP, Baynam G, Kaufmann P, Dawkins HJ, Lasko P, Austin CP, Boycott KM; IRDiRC Consortium Assembly. The International Rare Diseases Research Consortium: Policies and Guidelines to maximize impact. Eur J Hum Genet. 2017; 25:1293-1302.
47. Cutillo CM, Austin CP, Groft SC. A Global Approach to Rare Diseases Research and Orphan Products Development: The International Rare Diseases Research Consortium (IRDiRC). In: Rare Diseases Epidemiology: Update and Overview (Posada de la Paz M, Taruscio D, Groft SC, eds.). Springer International Publishing, Cham, Switzerland, 2017; pp. 349-369.
48. Taruscio D, Floridia G, Salvatore M, Groft SC, Gahl WA. Undiagnosed Diseases: Italy-US Collaboration and International Efforts to Tackle Rare and Common Diseases Lacking a Diagnosis. In: Rare Diseases Epidemiology: Update and Overview (Posada de la Paz M, Taruscio D, Groft SC, eds.). Springer International Publishing, Cham, Switzerland, 2017; pp. 25-38.
49. Wellman-Labadie O, Zhou Y. The US Orphan Drug Act: Rare disease research stimulator or commercial opportunity? Health Policy. 2010; 95:216-228.
50. Seoane-Vazquez E, Rodriguez-Monguio R, Szeinbach SL, Visaria J. Incentives for orphan drug research and development in the United States. Orphanet J Rare Dis. 2008; 3:33.
51. Haffner ME. History of Orphan Drug Regulation-United States and Beyond. Clin Pharmacol Ther. 2016; 100:342-343.
52. Rhee TG. Policymaking for Orphan Drugs and Its Challenges. AMA J Ethics. 2015; 17:776-779.
53. Lichtenberg FR. The impact of new (orphan) drug approvals on premature mortality from rare diseases in the United States and France, 1999-2007. Eur J Health Econ. 2013; 14:41-56.
54. Daniel MG, Pawlik TM, Fader AN, Esnaola NF, Makary MA. The Orphan Drug Act: Restoring the Mission to Rare Diseases. Am J Clin Oncol. 2016; 39:210-213.
55. Groft SC, Rubinstein YR. New and evolving rare diseases research programs at the National Institutes of Health. Public Health Genomics. 2013; 16:259-267.
56. Lewis J, Snyder M, Hyatt-Knorr H. Marking 15 years of the Genetic and Rare Diseases Information Center. Transl Sci Rare Dis. 2017; 2:77-88.
57. Cheng I. Research Office Legislative Council Secretariat. Information Note: Rare disease policies in selected places. https://www.legco.gov.hk/research-publications/english/1617in07-rare-disease-policies-in-selected-places-20170317-e.pdf (accessed July 30, 2018).
58. Baldovino S, Moliner AM, Taruscio D, Daina E, Roccatello D. Rare Diseases in Europe: from a Wide to a Local Perspective. Isr Med Assoc J. 2016; 18:359-363.
59. Whyte B. EU adopts legislation to promote drug development for rare diseases. Bull World Health Organ. 2000; 78:711-711.
60. European Commission. Regulation (EC) No 141/2000 of the European Parliament and of the council of 16 December 1999 on orphan medicinal products. Official Journal of the European Communities. 2000; L18/1-L18/5.
61. EURORDIS. France - EUROPLAN National Conference Final Report. http://www.eurordis.org/sites/default/files/flags/finalreport-france.pdf (accessed July 30, 2018).
62. UK Department of Health. The UK Strategy for Rare Diseases. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/260562/UK_Strategy_for_ Rare_Diseases.pdf (accessed July 30, 2018).
63. EUROPLAN. NAMSE: German National Plan of Action for People with Rare Diseases. http://www.europlanproject.eu/DocumentationAttachment/NATIONALPLANS_ GERMAN_2013_en.pdf (accessed July 30, 2018).
64. Congiu ME. The Italian National Plan for Rare Diseases. Blood Transfus. 2014; 12:s614-s616.
65. EURORDIS. Spain - EUROPLAN National Conference Final Report. http://www.eurordis.org/sites/default/files/finalreport-spain.pdf (accessed July 30, 2018).
66. Iskrov G, Miteva-Katrandzhieva T, Stefanov R. Challenges to orphan drugs access in Eastern Europe: The case of Bulgaria. Health Policy. 2012; 108:10-18.
67. Song P, Gao J, Inagaki Y, Kokudo N, Tang W. Intractable and rare diseases research in Asia. Biosci trends. 2012; 6:48-51.
68. Song P, Kokudo N. Revision of measures to combat intractable diseases in Japan: Three pillars will play an even greater role in the future. Intractable Rare Dis Res. 2013; 2:33-34.
69. Song P, Tang W, Kokudo N. Rare diseases and orphan drugs in Japan: developing multiple strategies of regulation and research. Expert Opin Orphan Drugs. 2013; 1:681-683.
70. Senate of the Philippines. Fourteenth Congress of the Republic of the Philippines Second Regular Session. Senate. SBN 3087. http://www.senate.gov.ph/lisdata/103909260!.pdf(accessed July 30, 2018).
71. Cui Y, Han J. Defining rare diseases in China. Intractable Rare Dis Res. 2017; 6:148-149.
72. Mateus HE, Pérez AM, Mesa ML, Escobar G, Gálvez JM, Montaño JI, Ospina ML, Laissue P. A first description of the Colombian national registry for rare diseases. BMC Res Notes. 2017; 10:514.